Pharmacodynamic Comparison of Truncal Blocks in Patients With or Without Metabolic Disease (Kidney Failure, Diabetes)

The primary objective is to demonstrate a longer period of neurologic recovery from a sensory block assessed in each test group versus the group without metabolic disease.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Montpellier Cedex 05, France, 34295
        • Hôpital Lapeyronnie CHU de Montpellier
      • Quincy-sous-Sénart, France, 91480
        • Hôpital Privé Claude Galien
    • Gard
      • Nîmes Cedex 09, Gard, France, 30029
        • Centre Hospitalier Universitaire de Nîmes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Three patient populations schelduled for surgery on the hand or wrist. The three groups include (1) patients with no metabolic or neurologic disease history, (2) patients with renal insufficiency but not diabetes and (3) patients with diabetes but not renal insufficiency.

Description

General Inclusion Criteria:

  • The patient must have given his/her informed and signed consent
  • The patient must be insured or beneficiary of a health insurance plan
  • The patient is available for 1 month of follow up
  • The patient is scheduled for hand or wrist surgery

Inclusion Criteria for the "Renal Insufficiency" group

  • Patient has renal insufficiency as defined by a creatine clearance of < 30ml/min without dialysis

Inclusion Criteria for the "Diabetes" group

  • Patient has chronic hyperglycemia, either a fasting glycemia > 1.26 g/l (7mmol/l) for longer than 5 years and receiving an oral, well-adjusted (last HBA1c < 6.5%)), non-insulin, antidiabetic treatment

Inclusion Criteria for the "Non-exposed" group

  • Patient without metabolic or neurologic disease, with creating clearance > 90ml/min

Exclusion Criteria:

  • The patient is participating in another study
  • The patient is in an exclusion period determined by a previous study
  • The patient is under judicial protection, under tutorship or curatorship
  • The patient refuses to sign the consent
  • It is impossible to correctly inform the patient
  • The patient is pregnant
  • The patient is breastfeeding
  • Patient weighs less than 50 kg
  • Score ASA > 4
  • contra indication for locoregional anesthesia
  • Severe metabolic and / or decompensated renal disease, cardiac or pulmonary decompensation
  • Associated peripheral neuropathy associated with diabetes or kidney disease
  • Associated central neuropathy associated (eg MS ... narrow cervical canal)
  • Patients with both renal failure and diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Renal insufficiency group
Patients in this group have renal insufficiency as defined by a creatinine clearance of < 30 ml/min without dialysis. These patients do not have diabetes.
Patients will have a truncal block during hand or wrist surgery.
Diabetic group
These patients have diabetes, but not renal insufficiency.
Patients will have a truncal block during hand or wrist surgery.
Non-exposed group
These patients have neither a neurological nor a metabolic disease and a creatine clearance of > 90 ml/min
Patients will have a truncal block during hand or wrist surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The duration of sensory block in minutes.
Time Frame: Day 0 (per-op)
The duration of the sensory block in minutes. The beginning of this term is defined by the end of the axillary block (last injection), and the end of this period is defined by the reappearance of sensitivity to touch in the area anesthetized.
Day 0 (per-op)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time necessary for completion of axillary blocks (1 / 3 upper humerus)(min)
Time Frame: Day 0 (per-op)
Day 0 (per-op)
Time necessary for installing sensory and motor block (min)
Time Frame: Day 0 (per-op)
Time necessary for installing sensory and motor block (min): defined by the delay between the end of the block injection and the occurrence of insensitivity of blocked territories
Day 0 (per-op)
Failure of the block: yes / no
Time Frame: Day 0 (per-op)
Failure of the block: yes / no: defined by an absence of sensory block
Day 0 (per-op)
Presence of paresthesia: yes / no
Time Frame: Day 0 (per-op)
Day 0 (per-op)
Occurrence of neurological complications, yes/no
Time Frame: Day 0 (post-op)
Neurological: occurrence of complications (paresthesia, paralysis, paresis ....) that persist (or not) until the final postoperative evaluation
Day 0 (post-op)
Occurrence of neurological complications, yes/no
Time Frame: 1 month
Occurrence of neurological complications (paresthesia, paralysis, paresis ....)
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Philippe Cuvillon, MD, Centre Hospitalier Universitaire de Nîmes

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2011

Primary Completion (Actual)

July 1, 2013

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

March 24, 2011

First Submitted That Met QC Criteria

March 24, 2011

First Posted (Estimate)

March 25, 2011

Study Record Updates

Last Update Posted (Estimate)

March 26, 2015

Last Update Submitted That Met QC Criteria

March 25, 2015

Last Verified

March 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • LOCAL/2010/PC-02
  • 2010-024519-15 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes

Clinical Trials on Truncal block

3
Subscribe